Protalix BioTherapeutics (PLX) Return on Capital Employed Growth (3y) (2016 - 2026)
Protalix BioTherapeutics (PLX) Return on Capital Employed Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -356.00 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -516.00 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -4,078.00 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4,967.00 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5,777.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -9,445.00 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 109.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 513.00 |
| 10 | Protalix BioTherapeutics | 189.97 Mn | 149.31 Mn | 12.13 Mn | 838.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 838.00 |
| Mar 31, 2026 | 7,634.00 |
| Dec 31, 2025 | 4,478.00 |
| Sep 30, 2025 | 7,747.00 |
| Jun 30, 2025 | 6,045.00 |
| Mar 31, 2025 | 6,156.00 |
| Dec 31, 2024 | 5,443.00 |
| Sep 30, 2024 | 543.00 |
| Jun 30, 2024 | 9,115.00 |
| Mar 31, 2024 | 15,131.00 |
| Dec 31, 2023 | 4,242.00 |
| Sep 30, 2023 | 2,306.00 |
| Jun 30, 2023 | 1,378.00 |
| Mar 31, 2023 | -4,290.00 |
| Dec 31, 2022 | 5,955.00 |
| Sep 30, 2022 | 1,180.00 |
| Jun 30, 2022 | 1,377.00 |
| Mar 31, 2022 | 565.00 |
| Dec 31, 2021 | 562.00 |
| Sep 30, 2021 | 5,086.00 |